Latest Innovation News

National Australia Bank reported a modest rise in underlying profit for FY25, driven by robust revenue and volume growth in the second half, alongside continued technology modernization and sustainability progress.

Santana Minerals has been granted a 30-year mining permit for its Bendigo-Ophir Gold Project in Central Otago, surpassing earlier expectations of a 25-year term and providing long-term operational certainty.

Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.

Mesoblast is set to meet the FDA in December to discuss compelling Phase 3 data showing its cell therapy rexlemestrocel-L may significantly reduce opioid use in chronic low back pain patients. This meeting could mark a pivotal step in addressing the US opioid crisis through innovative regenerative medicine.

EnergyX’s share price hike to US$11 signals renewed investor confidence and a lithium market rebound, increasing Pantera Lithium’s holding value by A$5.4 million.

RAS Technology Holdings has landed a significant contract to provide racing data and managed trading services for LeoVegas Group’s UK brands, including BetMGM UK, marking a strategic expansion into regulated markets.

FBR Limited has inked a non-binding Memorandum of Understanding with Fraser Lyne Constructions for the sale of a Hadrian® bricklaying robot unit valued at A$7.8 million, aiming to tackle New South Wales' housing shortage with advanced automation.

ARC Funds Limited has strategically acquired $2.15 million face value of convertible notes in ausbiz TV at just 20% of their value, issuing 4.47 million new shares as consideration. This move aligns with ARC’s growth strategy to diversify income streams and deepen its investment platform.

Impact Minerals is reigniting exploration at its vast Broken Hill project in NSW, leveraging rising metal prices and a proprietary multi-metal ratio to uncover high-grade platinum group metals and base metals.

ReNerve Limited is scaling up its clinical trial for the NervAlign® Nerve Cuff following promising interim results that show significant pain reduction in nerve repair patients. The expanded study aims to solidify evidence for broader regulatory approval and market adoption.

Tryptamine Therapeutics has raised $6.1 million to fast-track clinical development of its IV-infused psilocin drug TRP-8803, targeting binge eating disorder and other neuropsychiatric conditions.

Nanosonics Limited has announced a $20 million on-market share buy-back program for FY26, underscoring its robust financial health and confidence in future growth driven by new product innovations.